Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LCK | P06239 | 5/20 | 0.41 |
| ▸ | CA1 | P00915 | 1/20 | 0.41 |
| ▸ | CA2 | P00918 | 1/20 | 0.41 |
| ▸ | NAMPT | P43490 | 2/20 | 0.40 |
| ▸ | CYP17A1 | P05093 | 1/20 | 0.39 |
| ▸ | ATR | Q13535 | 1/20 | 0.39 |
| ▸ | PSMB8 | P28062 | 1/20 | 0.37 |
| ▸ | CCNB2 | O95067 | 1/20 | 0.37 |
| ▸ | CCNE2 | O96020 | 1/20 | 0.37 |
| ▸ | CDK1 | P06493 | 1/20 | 0.37 |
| ▸ | CDK4 | P11802 | 1/20 | 0.37 |
| ▸ | CCNB1 | P14635 | 1/20 | 0.37 |
| ▸ | CCND1 | P24385 | 1/20 | 0.37 |
| ▸ | CCNE1 | P24864 | 1/20 | 0.37 |
| ▸ | CDK2 | P24941 | 1/20 | 0.37 |
| ▸ | CCNB3 | Q8WWL7 | 1/20 | 0.37 |
| ▸ | FPR3 | P25089 | 2/20 | 0.37 |
| ▸ | FPR2 | P25090 | 2/20 | 0.37 |
| ▸ | METAP1 | P53582 | 1/20 | 0.37 |
| ▸ | HDAC3 | O15379 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14507524 | 0.84 | CA1 (0.41) | LCKCA1CA2NAMPTCYP17A1 | |
| SCHEMBL25406465 | 0.83 | CA1 (0.40) | LCKCA1CA2NAMPTCYP17A1 | |
| SCHEMBL13955004 | 0.83 | ATR (0.41) | LCKCA1CA2NAMPTCYP17A1 | |
| SCHEMBL19455034 | 0.83 | CA1 (0.43) | LCKCA1CA2NAMPTCYP17A1 | |
| SCHEMBL23165117 | 0.81 | ATR (0.46) | LCKCA1CA2NAMPTCYP17A1 | |
| SCHEMBL15235889 | 0.80 | CYP17A1 (0.39) | LCKCA1CA2NAMPTCYP17A1 | |
| SCHEMBL3114014 | 0.80 | CA1 (0.42) | LCKCA1CA2NAMPTCYP17A1 | |
| SCHEMBL18071028 | 0.80 | CA1 (0.39) | LCKCA1CA2NAMPTCYP17A1 | |
| SCHEMBL3102171 | 0.79 | CA1 (0.38) | LCKCA1CA2NAMPTCYP17A1 | |
| SCHEMBL29803713 | 0.79 | NAMPT (0.49) | CA1CA2NAMPTHDAC1HDAC6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 73 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4041730-B1 | SUBSTITUTED BICYCLIC HETEROARYL COMPOUNDS | BRISTOL MYERS SQUIBB CO (US) | 2026-05-13 | — | — | EP | disclosed |
| US-12545649-B2 | WDR5-MYC inhibitors | VANDERBILT UNIVERSITY (US) | 2026-02-10 | — | — | US | disclosed |
| US-20250346585-A1 | PHARMACEUTICAL COMPOUNDS FOR THE TREATMENT OF COMPLEMENT MEDIATED DISORDERS | ALEXION PHARMACEUTICALS, INC. (US) | 2025-11-13 | — | — | US | disclosed |
| US-20250338846-A1 | COMPOSITIONS HAVING PESTICIDAL UTILITY AND PROCESSES RELATED THERETO | CORTEVA AGRISCIENCE, LLC (US) | 2025-11-06 | — | — | US | disclosed |
| US-12448395-B2 | Substituted bicyclic heteroaryl compounds | BRISTOL-MYERS SQUIBB COMPANY (US) | 2025-10-21 | — | — | US | disclosed |
| EP-4619406-A1 | TRICYCLIC COMPOUNDS | Schrödinger, Inc. (US) | 2025-09-24 | — | — | EP | disclosed |
| EP-4525618-A2 | COMPOSITIONS HAVING PESTICIDAL UTILITY AND PROCESSES RELATED THERETO | Corteva Agriscience LLC (US) | 2025-03-26 | — | — | EP | disclosed |
| CN-114761404-B | Substituted bicyclic heteroaryl compounds | 百时美施贵宝公司 | 2025-02-21 | — | — | CN | disclosed |
| WO-2024107393-A1 | TRICYCLIC COMPOUNDS | SCHRÖDINGER, INC. (US) | 2024-05-23 | — | — | WO | disclosed |
| US-20240124489-A1 | SUBSTITUTED BICYCLIC HETEROARYL COMPOUNDS | BRISTOL MYERS SQUIBB CO (US) | 2024-04-18 | — | — | US | disclosed |
| EP-2173728-A2 | HETEROCYCLIC MODULATORS OF PKB | Amgen Inc. (US) | 2010-04-14 | — | — | EP | disclosed |
| EP-2170892-A2 | IMIDAZOPYRAZINES AS PROTEIN KINASE INHIBITORS | SCHERING CORPORATION (US) | 2010-04-07 | — | — | EP | disclosed |
| US-20090275592-A1 | Heterocyclic modulators of PKB | AMGEN INC. (US) | 2009-11-05 | — | — | US | disclosed |
| US-20090275592-A1 | Heterocyclic modulators of PKB | AMGEN INC. (US) | 2009-11-05 | — | — | US | disclosed |
| US-20090275592-A1 | Heterocyclic modulators of PKB | AMGEN INC. (US) | 2009-11-05 | — | — | US | disclosed |
| WO-2009017701-A2 | ANTI-MITOTIC AGENT AND AURORA KINASE INHIBITOR COMBINATION AS ANTI-CANCER TREATMENT | SCHERING CORPORATION (US) | 2009-02-05 | — | — | WO | disclosed |
| WO-2009011880-A2 | HETEROCYCLIC MODULATORS OF PKB | AMGEN INC. (US) | 2009-01-22 | — | — | WO | disclosed |
| WO-2009011880-A2 | HETEROCYCLIC MODULATORS OF PKB | AMGEN INC. (US) | 2009-01-22 | — | — | WO | disclosed |
| WO-2008156614-A2 | IMIDAZOPYRAZINES AS PROTEIN KINASE INHIBITORS | SCHERING CORPORATION (US) | 2008-12-24 | — | — | WO | disclosed |
| WO-2008156614-A2 | IMIDAZOPYRAZINES AS PROTEIN KINASE INHIBITORS | SCHERING CORPORATION (US) | 2008-12-24 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250338846-A1 | COMPOSITIONS HAVING PESTICIDAL UTILITY AND PROCESSES RELATED THERETO | ACHE, DDT, PLA2G2D | LCK 1463/4885CA1 2225/4885CA2 859/4885 |
| US-20240124489-A1 | SUBSTITUTED BICYCLIC HETEROARYL COMPOUNDS | TLR7, TLR1, TLR9 | LCK 205/4885CA1 4425/4885CA2 3796/4885 |
| US-12545649-B2 | WDR5-MYC inhibitors | MYC, MYCBP, WDR1 | LCK 3616/4885CA1 4372/4885CA2 3178/4885 |
| US-20090275592-A1 | Heterocyclic modulators of PKB | MTOR, PDK1, EIF4EBP1 | LCK 851/4885CA1 4332/4885CA2 2961/4885 |
| US-20250346585-A1 | PHARMACEUTICAL COMPOUNDS FOR THE TREATMENT OF COMPLEMENT MEDIATED DISORDERS | C5, C1S, C9 | LCK 2160/4885CA1 4723/4885CA2 4475/4885 |
| US-12448395-B2 | Substituted bicyclic heteroaryl compounds | TLR7, TLR1, TLR9 | LCK 205/4885CA1 4425/4885CA2 3796/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.